PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Clifford Chance advises CCM Pharma Midco on its acquisition of Amdipharm

Law firm Clifford Chance has advised CCM Pharma Midco, a vehicle formed by Cinven Funds, on its purchase of Amdipharm.



The transaction values Amdipharm at GBP365m.

Amdipharm is a family-owned international niche pharmaceuticals business founded by Bhikhu and Vijay Patel, which buys "legacy products" – typically off-patent generic drugs in niche disease areas.

Cinven client relationship partner Jonny Myers says: "Clifford Chance is delighted to have advised Cinven on this deal, the second acquisition we have worked on together in as many months."

In August the firm acted for Cinven on its acquisition of the generics business Mercury Pharma. The businesses will have a combined enterprise value of GBP830m.

The Clifford Chance team was led by corporate partners Jonny Myers and Brendan Moylan who were assisted by associates Chris Sullivan, Toby Parkinson, Catriona Llanwarne.

Financing advice was provided by banking and finance partner Roderick McGillivray with support from Martin Forbes. Corporate associates Stuart Padgham and Ed Freeman advised on complex separation issues as well as commercial contracts.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured